<DOC>
	<DOCNO>NCT01256905</DOCNO>
	<brief_summary>The purpose study evaluate drug commonly use treat excessive day-time sleepiness , call armodafinil ( Nuvigil ) , also effective improve impairment attention commonly report patient advance Parkinson 's disease ( PD ) Lewy body disease ( LBD ) .</brief_summary>
	<brief_title>Attention Modulation Treatment Parkinson 's Disease Dementia With Lewy Bodies</brief_title>
	<detailed_description>The main aim study : 1 . To investigate whether PDD DLB th specific disturbance basal ganglia thalamocortical network , measure Electroencephalography ( EEG ) frequency analysis , ameliorate armodafinil . Our main hypothesis armodafinil restore attention improve cognitive disturbance PDD DLB , specific effect striatal-thalamo-cortical activity .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Established criterion diagnosis PDD ( Parkinsons Disease ) { Emre M et al . Mov Disord 2007 ; 22:1689707 } DLB ( Lewy Bodies Disease ) { McKeith et al . Neurology 2005 ; 65:186372 } Mini Mental State Examination ( MMSE ) score &lt; 24 ; and/or Dementia Rating Scale2 ( DRS2 ) score &lt; 134 ; Clinical Assessment Fluctuation ( CAF ) &gt; 4 ; Stable antiparkinsonian medication 4 week precede study Use cognitive enhancer ( Donepezil , Rivastigmine , Galantamine , Modafinil , Memantine ) last 4 week : Concomitant use medication contraindicate modafinil/armodafinil ; History alcohol substance abuse . Use medication know alter normal EEG activity human study period ( i.e . clonazepam ) History psychiatric disorder , depression psychiatric complication PDD DLB</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>